TickerFacts.

TFA Therapeutics, Inc. (RAJAF): Revenue

Annual figures by period end, from SEC filings.

$1.25M
Year ended 2025-12-31
+185.9%
3-year compound annual growth
$1.25M2021-12-31: $879.3K2022-12-31: $53.3K2023-12-31: $882.5K2024-12-31: $1.25M2025-12-31: $1.25M$1.25M
2021-12-31 Revenue (USD) 2025-12-31
Period endedRevenueChange YoYSource filing
2025-12-31$1.25M-0.6%2026-05-15, From 2025-01-01
2024-12-31$1.25M+42.0%2026-05-15, From 2024-01-01
2023-12-31$882.5Kn/m2026-05-15, From 2023-01-01
2022-12-31$53.3K-93.9%2025-09-23, From 2022-01-01
2021-12-31$879.3Kn/a2023-05-15, From 2021-01-01

Revenue at similar companies

Companies with the same SEC industry code (Medicinal Chemicals & Botanical Products), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedRevenueChange YoY
TFA Therapeutics, Inc. (RAJAF)2025-12-31$1.25M-0.6%
Adia Med, Inc. (ADIA)2025-12-31$700.5Kn/m
Target Group Inc. (CBDY)2025-12-31$3.88M-41.1%
Healthy Extracts Inc. (HYEX)2025-12-31$4.51M+44.9%
China Foods Holdings Ltd. (CFOO)2025-12-31$327.9K+40.5%
Nutra Pharma Corp (NPHC)2025-12-31$257.6K+4.6%
Functional Brands Inc. (MEHA)2025-12-31$6.61M+0.7%
Bon Natural Life Ltd (BON)2025-09-30$18.67M-21.7%
Charlie's Holdings, Inc. (CHUC)2025-12-31$20.92M+169.4%

Compare RAJAF, ADIA, CBDY, HYEX side by side · Screen every company in Medicinal Chemicals & Botanical Products ↗